Previous studies investigating DPP-4 inhibitor therapy mainly sitagliptin and vildagliptin, in a type 2 diabetes population found that there was no significant reduction in HbA1c values with treatment [42]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.